ArticleJournal of thoracic disease2022

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma-successes and challenges.

Eziafa I Oduah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.